Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
Holding CODX?
Track your performance easily
CODX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $2.23
Previous Close$0.76
Volume251.69K
Average Volume (3M)111.20K
Market Cap
$24.27M
Enterprise Value-$11.03M
Total Cash (Recent Filing)$37.66M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Apr 08, 2025EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding31,929,752
10 Day Avg. Volume144,074
30 Day Avg. Volume111,200
Standard Deviation0.57
R-Squared0.00711
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)0.38
Price to Sales (P/S)3.55
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.51
Enterprise Value/Gross Profit-4.20
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$1.50Price Target Upside106.73% Upside
Rating ConsensusHold
Number of Analyst Covering1
Co-Diagnostics News
PremiumCompany Announcements
Co-Diagnostics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company plans to initiate clinical trials of the TB test in both South Africa and India and start a clinical trial of the respiratory multiplex test during the flu season.
Financial PerformanceTotal revenue was $2.7M, beating analyst's projection of $0.4M due to $2.5M of grant revenue based on achievement of certain milestones.
Regulatory ReviewThe FDA is currently reviewing the company’s 510(k) application for the Co-Dx PCR Pro instrument and the Co-Dx PCR COVID-19 test for over-the-counter use.
Bears Say
Financial LossNet loss was $7.6M, or ($0.25) per share, lower than the estimated loss of $10.6M.
Regulatory And Product RisksRisks include lower than projected uptake of products, inability to maintain regulatory compliance, inability to develop additional products targeting infectious diseases, and dilution risk.
Revenue DeclineTotal revenue was $0.6M, representing 74% YoY decline.
---
Ownership Overview
5.09% Insiders
7.40% Mutual Funds
1.38% Other Institutional Investors
80.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $0.73 and its highest was $2.23 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Currently, no data Available
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Apr 08, 2025 which is in 110 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Nov 07, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.01.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -$0.34.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 31,929,752 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Among the largest hedge funds holding Co-Diagnostics Inc’s share is Hussman Strategic Advisors Inc. It holds Co-Diagnostics Inc’s shares valued at N/A.
---
Co-Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (106.73% Upside)
$1.50 (106.73% Upside)
Hedge Fund Trend
Decreased
By 36.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.33%
12-Months-Change
Fundamentals
Return on Equity
-50.57%
Trailing 12-Months
Asset Growth
-33.40%
Trailing 12-Months
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
---
CODX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development and international expansion of Co-Diagnostics' platforms and tests. However, the company faces challenges with decreased revenue, increased net losses, and uncertainty around FDA approvals.Read More>---
CODX Stock 12 Month Forecast
Average Price Target
$1.50
▲(106.73% Upside)
Technical Analysis
---